Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 407

The DOI matches its Crossref record; 303 of the 303 references it cites were found in a registry or an index.

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Open access
Colombo, N, Sessa, C, Bois, A du, Ledermann, J, McCluggage, WG, McNeish, I, Morice, P, Pignata, S, Ray-Coquard, I, Vergote, I, Baert, T, Belaroussi, I, Dashora, A, Olbrecht, S, Planchamp, F, Querleu, D·2019·International Journal of Gynecological Cancer

Abstract

The development of guidelines is one of the core activities of the European Society for Medical Oncology (ESMO) and European Society of Gynaecologial Oncology (ESGO), as part of the mission of both societies to improve the quality of care for patients with cancer across Europe. ESMO and ESGO jointly developed clinically relevant and evidence-based recommendations in several selected areas in order to improve the quality of care for women with ovarian cancer. The ESMO–ESGO consensus conference on ovarian cancer was held on April 12–14, 2018 in Milan, Italy, and comprised a multidisciplinary panel of 40 leading experts in the management of ovarian cancer. Before the conference, the expert panel worked on five clinically relevant questions regarding ovarian cancer relating to each of the following four areas: pathology and molecular biology, early-stage and borderline tumours, advanced stage disease and recurrent disease. Relevant scientific literature, as identified using a systematic search, was reviewed in advance. During the consensus conference, the panel developed recommendations for each specific question and a consensus was reached. The recommendations presented here are thus based on the best available evidence and expert agreement. This article presents the recommendations of this ESMO–ESGO consensus conference, together with a summary of evidence supporting each recommendation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/ijgc-2019-000308

Cites

303 of 303 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 303 references

Research works printed but not linked: 5

  1. Trimbos, 2003, Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-AdjuvanT Chemotherapy in Ovarian Neoplasm Trial, J Natl Cancer Inst, 95, 113, 10.1093/jnci/95.2.113 · DOI · Paper page
  2. Tropé, 1997, Randomized trial on adjuvant carboplatin versus no treatment in stage I high risk ovarian cancer by the Nordic Ovarian Cancer Study Group (NOCOVA) [abstract], Proceedings of the American Society of Clinical Oncology, 16
  3. Clamp, 2017, Ann Oncol, 28
  4. Coleman, 2018, J Clin Oncol, 36
  5. Guastalla, 2002, CA125 evaluation of chemotherapy response in patients with recurrent ovarian cancer: Rustin criteria revisited, Proc Am Soc Clin Oncol, 21

Cited by

See all 407

Metadata

Authors
Colombo, N., Sessa, C., Bois, A. D., Ledermann, J., McCluggage, W., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., Baert, T., Belaroussi, I., Dashora, A., Olbrecht, S., Planchamp, F., & Querleu, D.
Venue
International Journal of Gynecological Cancer
Publisher
Elsevier BV
Published
2019-05
Volume
29
Issue
4
Pages
728-760
ISSN
1048-891X (ISSN-L)
OpenAlex
W2943306812
Cited by
407
References
303
FWCI
36.82
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. https://app.cochat.ai/papers/10.1136/ijgc-2019-000308
The paper
Colombo, N., Sessa, C., Bois, A. D., Ledermann, J., McCluggage, W., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., Baert, T., Belaroussi, I., Dashora, A., Olbrecht, S., Planchamp, F., & Querleu, D. (2019). ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. International Journal of Gynecological Cancer. https://doi.org/10.1136/ijgc-2019-000308

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.